Tilray's CC Pharma enters U.K. distribution deal

Executive Summary

• Tilray Pharma’s European distribution arm, CC Pharma, entered into a strategic agreement with UK-based Smartway Pharmaceuticals to expand the availability of pharmaceutical products across the United Kingdom.
• The partnership leverages Smartway’s national distribution infrastructure and CC Pharma’s European procurement and GMP manufacturing capabilities to accelerate parallel import and specialist pharmaceutical supply in the UK.
• The agreement aims to embed Tilray into the UK health system for its medicinal cannabis products and capitalize on a UK market estimated at nearly £1 billion within this specific category.

Key Details

• Parties Involved: CC Pharma (subsidiary of Tilray Brands Inc.) and Smartway Pharmaceuticals (UK-based distributor).
• Strategic Focus: Expansion of parallel import and specialist pharmaceutical supply in the United Kingdom.
• Operational Synergy: Utilization of Smartway’s established national distribution network combined with CC Pharma’s European procurement capability and Good Manufacturing Practice (GMP) capacity.
• Market Context: The specific UK pharmaceutical market category targeted is estimated at nearly £1 billion.
• Strategic Goal: To broaden access to medicinal products through established healthcare channels, improve supply reliability, and embed Tilray into the UK health system specifically for medicinal cannabis products.
• Relationship History: CC Pharma and Smartway have maintained a collaboration relationship since 2009.
• Future Outlook: Both companies will explore additional opportunities for broader collaboration to support Tilray’s strategy of building scaled, partnership-led platforms in key international healthcare markets.

Notable Quotes

• Rajnish Ohri, President, International, Tilray Brands: "The U.K. is a priority market within Tilray's international medical strategy. This agreement strengthens our ability to broaden access to medicinal products through established health care distribution channels, while advancing our long-term growth across Europe's evolving medical landscape. Further, this agreement is expected to embed Tilray into the U.K. health system for its own medicinal cannabis products."
• Mathias Bossen, Managing Director, CC Pharma: "This agreement represents an important step forward in expanding our pharmaceutical distribution activities into the U.K. By working closely with Smartway and leveraging their strong national network, we are well positioned to enhance supply reliability and support pharmacy and hospital partners with high-quality PI product lines across the U.K."
• Josh Cocklin, Chief Executive, Smartway: "Our focus is always on patients and outcomes. By extending what Smartway already does in regulated pharmaceutical supply, this agreement supports continuity and expansion of access to medicines across U.K. health care. For patients and the health care practitioners who care for them, this means fewer interruptions and more predictable access to care."